Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2025
Spring on the Road
Spring Wellness 2025
Canada Votes 2025
2024 Readers' Choice Awards
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Ontario Votes
LAST CHANCE AUCTION
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
NovoCure Limited - Ordinary Shares
(NQ:
NVCR
)
17.80
-0.20 (-1.11%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 30, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about NovoCure Limited - Ordinary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
18
19
Next >
Novocure to Report Second Quarter 2025 Financial Results
June 30, 2025
From
Novocure
Via
Business Wire
Demystifying NovoCure: Insights From 4 Analyst Reviews
June 27, 2025
Via
Benzinga
Applied Digital And Riot Platforms Are Among Top 10 Mid-Cap Gainers Last Week (Jun 2-Jun 6): Are The Others In Your Portfolio?
June 08, 2025
Via
Benzinga
NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial
June 02, 2025
TTField therapy with chemotherapy improved median overall and pain-free survival in pancreatic cancer, according to new data from the PANOVA-3 trial.
Via
Benzinga
Earnings Scheduled For April 24, 2025
April 24, 2025
Via
Benzinga
NovoCure's Earnings: A Preview
April 23, 2025
Via
Benzinga
Prediction: Novocure (NVCR) Will Beat the Market. Here's Why
March 04, 2025
Via
The Motley Fool
Earnings Scheduled For February 27, 2025
February 27, 2025
Via
Benzinga
Deep Dive Into NovoCure Stock: Analyst Perspectives (7 Ratings)
January 14, 2025
Via
Benzinga
Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
May 31, 2025
From
Novocure
Via
Business Wire
1 Stock Down 35% This Year You'll Regret Not Buying on the Dip, According to Wall Street
May 28, 2025
Via
The Motley Fool
Novocure Announces Upcoming Investor Events
May 27, 2025
From
Novocure
Via
Business Wire
Why NovoCure Stock Skyrocketed This Week
April 25, 2025
Via
The Motley Fool
Topics
Earnings
Stocks
Why NovoCure Stock Leaped 4% Higher Today
April 24, 2025
Via
The Motley Fool
NovoCure Warns Of Potential $11 Million Tariff Hit If US Trade Pause Expires In 2025
April 24, 2025
NovoCure posted a smaller-than-expected Q1 loss with 12% revenue growth, while monitoring tariff shifts that could impact 2025 costs.
Via
Benzinga
Topics
World Trade
NovoCure Surpasses Q1 Expectations
April 24, 2025
NovoCure posted stronger-than-expected Q1 2025 results, driven by revenue and GAAP earnings surpassing estimates.
Via
The Motley Fool
12 Health Care Stocks Moving In Thursday's Pre-Market Session
April 24, 2025
Via
Benzinga
Novocure Reports First Quarter 2025 Financial Results
April 24, 2025
From
Novocure
Via
Business Wire
Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting
April 23, 2025
From
Novocure
Via
Business Wire
Novocure’s Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer
April 22, 2025
From
Novocure
Via
Business Wire
Why NovoCure Stock Was Withering on Wednesday
April 16, 2025
Via
The Motley Fool
Novocure to Report First Quarter 2025 Financial Results
April 01, 2025
From
Novocure
Via
Business Wire
Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference
March 04, 2025
From
Novocure
Via
Business Wire
NovoCure (NVCR) Q4 2024 Earnings Call Transcript
February 27, 2025
NVCR earnings call for the period ending December 31, 2024.
Via
The Motley Fool
Topics
Earnings
NovoCure Reports Wider Than Expected Q4 Loss Despite 21% Jump In Sales, Expects Product Enhancements To Hit Gross Margin In 2025
February 27, 2025
NovoCure's Q4 revenue rose 21% to $161.27M, surpassing expectations, while its loss widened. Annual sales hit $605M, fueled by Optune Gio's expansion.
Via
Benzinga
NovoCure Q4 EPS Misses, Revenue Matches
February 27, 2025
NovoCure reported a solid jump in revenue, but earnings fell short due to rising costs and adoption challenges.
Via
The Motley Fool
Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update
February 27, 2025
From
Novocure
Via
Business Wire
Jim Cramer Likes This Tech Stock: 'Terrific Business, Niche Business'
January 30, 2025
On CNBC's "Mad Money Lightning Round," Jim Cramer recommended buying Keysight Technologies calling it a "Terrific business."
Via
Benzinga
Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update
January 13, 2025
From
Novocure
Via
Business Wire
Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference
January 03, 2025
From
Novocure
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
18
19
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.